Drupal.behaviors.print = function(context) {window.print();window.close();}>
Quanterix Study Suggests Simoa Platform Can Compete with Nucleic Acid-Based HIV Tests
October 12, 2012
Quanterix Study Suggests Simoa Platform Can Compete with Nucleic Acid-Based HIV Tests
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Plasmonic ELISA Offers High-Sensitivity Protein Assay Readable by the Naked Eye
November 2, 2012 / ProteoMonitor
Quanterix's AccuPSA Test Predicts Five-Year Recurrence-Free Survival in Prostate Cancer Study
October 21, 2011 / ProteoMonitor
Quanterix, Gothenberg Researchers Show Potential Link Between Heart Attacks and Alzheimer's Marker
April 15, 2011 / ProteoMonitor
BioMerieux Takes $15M Stake in Quanterix, Gains Exclusive Global License to SiMoA as IVD Platform
November 30, 2012 / ProteoMonitor
BioMerieux Invests $15M in Quanterix as Part of Test Development Partnership
November 15, 2012 / GenomeWeb Daily News